Cardiovascular & Hormonal Research Laboratory
Lab head: Dr Anastasia Susie Mihailidou
Location: Lvl 13, Kolling Building, Royal North Shore Hospital
Lab members: Dr Mahidu Mardini Dr Vincent Wong Mr Harris Mihailidis
Research approach equipment: We use established techniques which include Langendorff apparatus for the ischaemia-reperfusion studies, electrophysiology workstations for patch-clamping heart cells and also have access to histology equipment for immunohistochemistry and biochemical techniques and cell culture.
Le TYL, Ashton AW, Mardini M, Stanton PG, Funder JW, Handelsman DJ, Mihailidou AS (2014). Role of androgens in sex differences in cardiac damage during myocardial infarction. Endocrinology. 155: 568-575.
Mihailidou AS, Ashton AW (2014). “Cardiac effects of Aldosterone: does Gender matter?” in Special Issue: Extrarenal actions of aldosterone (mineralocorticoid receptor) (C Gomez-Sanchez, Series Editor). Steroids (In Press, August 2014).
Leung M, Wong VW, Heritier S, Mihailidou AS, Leung DY (2013). Rationale and design of a randomized trial on the impact of aldosterone antagonism on cardiac structure and function in diabetic cardiomyopathy. Cardiovascular Diabetology12: 139.
Phillips CL, Grunstein RR, Darendeliler MA, Mihailidou AS, Srinivasan VK, Yee BJ, Marks GB, Cistulli PA (2013). Comparison of Health Outcomes of CPAP versus Oral Appliance Treatment for Obstructive Sleep Apnea: A Randomised Controlled Trial. American Journal of Respiratory and Critical Care Medicine. 187: 879-887.
Ohkubo T, Mihailidou AS (2013). Is there a role for Day-to-day home blood pressure variability in guiding management of hypertension. Frontiers in Research Series in Clinical & Experimental Physiology & Pharmacology, ( In Press, Sep 2013).
Young MJ, Fuller PJ, Stowasser M, Mihailidou AS (2013). Frontiers in Research Review: Aldosterone and Salt: Heart and Kidney. Clinical and Experimental Pharmacology and Physiology.40: 872–875.
AS Mihailidou, R Ritchie, AW Ashton (2013). Sex Differences in Sudden Cardiac Death; In: Ischemic Heart Disease. Dr. David Gaze (Ed), ISBN 978-953-51-0993-8. InTech - Open Access Publisher.
AS Mihailidou (2012). "Aldosterone in Heart Disease" in Special Issue: Hypertension: Kidney, Sodium, and Renin-Angiotensin (R Carey & A Mimran, Section Editors). Current Hypertension Reports. 14: 125-129.
AS Mihailidou(2012). Ischemic Heart Disease, Diabetes and Mineralocorticoid Receptors; In: Novel Strategies in Ischemic Heart Disease, Umashankar Lakshmanadoss (Ed.), ISBN: 978-953-51-0184-0.
Buckley T, Stannard A, Bartrop R, McKinley S, Ward C, Mihailidou AS, Morel-Kopp M-C, Spinaze M, Stannard A, Tofler G (2012). Effect of Early Bereavement on Heart Rate and Heart Rate Variability. American Journal of Cardiology. 110: 1378 –1383.
Le L, Mardini M, Howell, V, Funder JW, Ashton AW, Mihailidou AS (2012). Low dose spironolactone prevents ARC (Apoptosis Repressor with a Caspase-recruitment domain) degradation during myocardial infarction. Hypertension. 59:1164-1169.
Head GA, McGrath BP, Mihailidou AS, Nelson MR, Schlaich MP, Stowasser M, Mangoni AA, Cowley D, Brown MA, Ruta L-A, Wilson J (2012). Ambulatory blood pressure monitoring in Australia: 2011 consensus position statement. Journal of Hypertension 30:253–266.
Buckley T, Morel-Kopp M-C, Ward C, Bartrop R, McKinley S, Mihailidou AS, Spinaze M, Chen W, Tofler G (2012). Inflammatory and Thrombotic Changes in Early Bereavement: a Prospective Evaluation. European Journal of Preventative Cardiology. Oct;19(5): 1145-1152.
Head GA, McGrath BP, Mihailidou AS, Nelson MR, Schlaich MP, Stowasser M, Mangoni AA, Cowley D, Brown MA, Ruta L-A, Wilson J (2011). What is ambulatory Blood Pressure Monitoring? Australian Family Physician 40:877-880.
Buckley T, Mihailidou AS, Bartrop R, McKinley S, Ward C, Morel-Kopp M-C, Spinaze M, Hocking B, Tofler G (2011). Hemodynamic changes during early bereavement: Potential contribution to increased cardiovascular risk. Heart Lung Circ. 20:91-98.
Wong V, Mardini M, Cheung W, Mihailidou AS (2011). High dose insulin in experimental myocardial infarction in rabbits: protection against effects of hyperglycaemia. Journal of Diabetes and Its Complications,25:122-128.
Buckley T, Morel-Kopp M-C, Ward C, Bartrop R, McKinley S, Mihailidou AS, Spinaze M, Chen W, Tofler G. Inflammatory and Thrombotic Changes in Early Bereavement: a Prospective Evaluation (submitted European Heart Journal 2010)
Head G, Mihailidou AS, Duggan K, Beilin LJ, BerryN, Brown MA, Bune A, Cowley D, Chalmers JP, Howe PRC, Hodgson J, Ludbrook J, Mangoni AA, McGrath BP, Morley CM, Nelson MR, Sharman JE, Stowasser M. Relationship between ambulatory and Clinic Blood Pressure: Defining diagnostic and treatment targets. (British Medical Journal, Online April 2010)
Mihailidou AS, Le TYL, Mardini M, Funder JW (2009). Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 54:1306-1312.
Funder JW, Mihailidou AS (2009). Aldosterone and mineralocorticoid receptors: Clinical studies and basic biology. Mol Cell Endocrinol 301: 2-6.
Buckley T, Bartrop R, McKinley S, Ward C, Bramwell M, Roche D, Mihailidou AS, Morel-Kopp M-C, Spinaze M, Hocking B, Goldston K, Tennant C, Tofler G. (2009). A Prospective study of early bereavement on psychological and behavioural cardiac risk factors. Internal Med J 39: 370-378.
Mihailidou AS (2006). Nongenomic actions of aldosterone: Physiological or pathophysiological role? Steroids 71: 277-280.
Mihailidou AS, Funder JW (2005). Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids 70: 347-351.
Mihailidou AS (2005). Review: Nongenomic cardiovascular actions of aldosterone: a receptor for all seasons? Endocrinology 146: 971-972.
Mihailidou AS, Mardini M and Funder JW (2004). Rapid, non-genomic effects of aldosterone in the heart medicated by ePKC. Endocrinology 145: 773-780.
Glucagon-Like Peptide-1 agonists, reperfusion injury and type 2 diabetes
Primary supervisor: Susie Mihailidou
Diabetes is the fastest growing disease worldwide and in the past two decades the prevalence has doubled in Australia, contributing to significant disability, with increased mortality and morbidity from acute myocardial infarction (AMI). Patients with diabetes have a two-fold increase in the risk of short- and long-term mortality after AMI. Current anti-hyperglycemic medications reduce morbidity and mortality in patients with diabetes, however diabetic patients continue to have 2- to 4-fold greater risk of myocardial infarction and heart failure. Additional treatment strategies are needed that prevent these cardiovascular complications in diabetes. The glucagon-like peptide 1 (GLP-1) agonists are an exciting new class of anti-hyperglycaemic medication that not only lower glucose levels, but also reduce weight and have protective effects on pancreatic islets. This project will evaluate the cardiac effects of Liraglutide, a GLP-1 agonist, to protect against AMI using Zucker fatty rats at 12 weeks as a model of type 2 diabetes. Our recent studies show that during myocardial ischemia-reperfusion, cardiac damage is aggravated in Zucker male rats at 12 weeks of age, an established animal model of type 2 diabetes. The studies will involve both functional studies and molecular techniques (immunohistochemistry, western blot analysis).
Co-supervisors: Anthony Ashton
Keywords: Cardiovascular diseases, Reperfusion injury, Diabetes